Clinical Trial Looks at Effectiveness of New Neurotoxin, DAXXIFY, for Spasmodic Dysphonia
New clinical trial evaluates the safety of DAXXIFY and compares the treatment response to botulinum toxin A in patients with adductor spasmodic dysphonia.
Continue Reading
Clinical Trial Looks at Effectiveness of New Neurotoxin, DAXXIFY, for Spasmodic Dysphonia